Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-centre, Open-label, Randomised Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral Sitamaquine Compared With Amphotericin B in the Treatment of Visceral Leishmaniasis Caused by L. Donovani in Endemic Areas.

NCT00381394 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00381394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00381394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-centre, Open-label, Randomised Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral Sitamaquine Compared With Amphotericin B in the Treatment of Visceral Leishmaniasis Caused by L. Donovani in Endemic Areas.
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
August 4, 2006
Completion date
September 14, 2007
Enrollment
61 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

leishmaniasis, visceral